drugset / Trial / NCT00223977

2 Doses of Ferrlecit Versus Oral Iron to Treat Iron-deficiency Anemia in Peritoneal Dialysis Patients.

NCT00223977

Phase 2/3 Completed 146 enrolled Watson Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a phase 3 clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive one of two levels of Ferrlecit or oral iron in a 1:1:1 ratio.

Timeline

Start
2003-12
Primary completion
2004-11
Completion
2008-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferrous Sulfate Diagnostic / imaging agent 325 mg Oral
Subject Sodium Ferric Gluconate Complex Unknown 125 mg
Subject Sodium Ferric Gluconate Complex Unknown 250 mg